Jelena Klawitter
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 15 | 2025 | 235 | 4.370 |
Why?
| | Metabolomics | 21 | 2025 | 727 | 2.910 |
Why?
| | Kidney | 21 | 2025 | 1495 | 2.600 |
Why?
| | Tandem Mass Spectrometry | 17 | 2026 | 576 | 2.590 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 221 | 2.140 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 846 | 1.790 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 594 | 1.750 |
Why?
| | Oxidative Stress | 18 | 2020 | 1339 | 1.620 |
Why?
| | Cyclosporine | 10 | 2019 | 265 | 1.600 |
Why?
| | Metabolome | 9 | 2025 | 384 | 1.300 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 436 | 1.190 |
Why?
| | Sirolimus | 9 | 2019 | 281 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.020 |
Why?
| | Kidney Transplantation | 11 | 2025 | 704 | 1.010 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 609 | 1.000 |
Why?
| | Biomarkers | 23 | 2025 | 4271 | 0.960 |
Why?
| | Energy Metabolism | 8 | 2022 | 935 | 0.900 |
Why?
| | Pravastatin | 4 | 2025 | 43 | 0.900 |
Why?
| | Proteomics | 14 | 2020 | 1195 | 0.880 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 865 | 0.870 |
Why?
| | Allografts | 1 | 2025 | 150 | 0.860 |
Why?
| | Tryptophan | 5 | 2024 | 181 | 0.840 |
Why?
| | Tacrolimus | 5 | 2025 | 196 | 0.750 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 74 | 0.740 |
Why?
| | Endocannabinoids | 4 | 2025 | 57 | 0.740 |
Why?
| | Kynurenine | 5 | 2024 | 114 | 0.730 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 439 | 0.720 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 965 | 0.720 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.710 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 570 | 0.680 |
Why?
| | Menopause | 3 | 2020 | 320 | 0.660 |
Why?
| | Arginine | 2 | 2024 | 262 | 0.660 |
Why?
| | Cannabinoids | 3 | 2024 | 182 | 0.640 |
Why?
| | Glomerular Filtration Rate | 11 | 2025 | 760 | 0.620 |
Why?
| | Mass Spectrometry | 10 | 2021 | 750 | 0.620 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 914 | 0.620 |
Why?
| | Myocardium | 2 | 2017 | 939 | 0.610 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 598 | 0.610 |
Why?
| | Adenosine | 3 | 2018 | 255 | 0.570 |
Why?
| | Coronary Care Units | 1 | 2018 | 26 | 0.570 |
Why?
| | Signal Transduction | 11 | 2021 | 5226 | 0.570 |
Why?
| | Piperazines | 3 | 2009 | 381 | 0.560 |
Why?
| | Pyrimidines | 4 | 2014 | 532 | 0.540 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.530 |
Why?
| | Urine | 1 | 2017 | 62 | 0.520 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.510 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 145 | 0.500 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 120 | 0.490 |
Why?
| | Male | 54 | 2026 | 72315 | 0.490 |
Why?
| | Length of Stay | 4 | 2025 | 1337 | 0.480 |
Why?
| | Chromatography, Liquid | 9 | 2026 | 454 | 0.470 |
Why?
| | Animals | 42 | 2024 | 38058 | 0.470 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4557 | 0.460 |
Why?
| | Plasma | 1 | 2017 | 225 | 0.460 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 86 | 0.460 |
Why?
| | Female | 52 | 2026 | 78271 | 0.460 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 279 | 0.450 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.440 |
Why?
| | Humans | 75 | 2026 | 144759 | 0.440 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 310 | 0.440 |
Why?
| | Disease Progression | 8 | 2025 | 2847 | 0.430 |
Why?
| | Limit of Detection | 7 | 2024 | 97 | 0.420 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.410 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.410 |
Why?
| | Kidney Diseases | 4 | 2021 | 427 | 0.410 |
Why?
| | Dronabinol | 3 | 2026 | 247 | 0.400 |
Why?
| | Cell Proliferation | 4 | 2024 | 2496 | 0.400 |
Why?
| | Oxylipins | 2 | 2025 | 47 | 0.400 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 127 | 0.390 |
Why?
| | Inflammation | 9 | 2025 | 2878 | 0.380 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.380 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.370 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.370 |
Why?
| | Proteome | 3 | 2016 | 518 | 0.370 |
Why?
| | Oncogene Proteins | 1 | 2012 | 61 | 0.370 |
Why?
| | Dinoprost | 5 | 2019 | 49 | 0.360 |
Why?
| | Mutation | 2 | 2022 | 4089 | 0.360 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 851 | 0.350 |
Why?
| | Plant Extracts | 2 | 2024 | 187 | 0.350 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 266 | 0.350 |
Why?
| | Rats | 16 | 2024 | 5597 | 0.340 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 164 | 0.340 |
Why?
| | Nitric Oxide | 4 | 2024 | 897 | 0.330 |
Why?
| | Mitochondria | 1 | 2017 | 984 | 0.330 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 285 | 0.330 |
Why?
| | Postoperative Complications | 3 | 2021 | 2919 | 0.320 |
Why?
| | Purines | 2 | 2022 | 187 | 0.320 |
Why?
| | Blotting, Western | 6 | 2012 | 1187 | 0.310 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 630 | 0.310 |
Why?
| | Hypoxia | 6 | 2024 | 1199 | 0.300 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 459 | 0.300 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 5992 | 0.300 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 359 | 0.300 |
Why?
| | Prostaglandins | 3 | 2022 | 94 | 0.300 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 62 | 0.290 |
Why?
| | Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
| | Autophagy | 3 | 2024 | 286 | 0.290 |
Why?
| | Glycolysis | 4 | 2012 | 339 | 0.290 |
Why?
| | Mice | 19 | 2024 | 18339 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2194 | 0.280 |
Why?
| | Infant | 10 | 2025 | 10034 | 0.280 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 17 | 0.280 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 20 | 0.280 |
Why?
| | Mice, Knockout | 7 | 2023 | 3121 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3540 | 0.270 |
Why?
| | Vascular Diseases | 2 | 2021 | 251 | 0.260 |
Why?
| | Case-Control Studies | 7 | 2024 | 3604 | 0.260 |
Why?
| | Amino Acids | 2 | 2025 | 521 | 0.260 |
Why?
| | Blood Vessels | 2 | 2019 | 171 | 0.260 |
Why?
| | Prospective Studies | 13 | 2025 | 7990 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 881 | 0.250 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3409 | 0.250 |
Why?
| | Time Factors | 8 | 2022 | 7173 | 0.250 |
Why?
| | Infant, Newborn | 8 | 2025 | 6429 | 0.240 |
Why?
| | Rats, Wistar | 6 | 2018 | 451 | 0.240 |
Why?
| | Microsomes, Liver | 2 | 2019 | 85 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2024 | 51 | 0.230 |
Why?
| | Child | 10 | 2025 | 22633 | 0.220 |
Why?
| | Swine | 3 | 2022 | 833 | 0.220 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 75 | 0.220 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2452 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
| | Treatment Outcome | 9 | 2025 | 11679 | 0.220 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 69 | 0.220 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.220 |
Why?
| | Young Adult | 12 | 2023 | 14105 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2025 | 415 | 0.210 |
Why?
| | Adult | 19 | 2026 | 40449 | 0.210 |
Why?
| | Adolescent | 10 | 2025 | 22428 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 17 | 0.200 |
Why?
| | Arachidonic Acids | 1 | 2024 | 43 | 0.200 |
Why?
| | Citrulline | 1 | 2024 | 46 | 0.200 |
Why?
| | Graft Rejection | 4 | 2017 | 540 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 41 | 0.190 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 26 | 0.190 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 110 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.190 |
Why?
| | Tissue Distribution | 2 | 2014 | 327 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2061 | 0.190 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 26 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 587 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 509 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.180 |
Why?
| | Double-Blind Method | 6 | 2025 | 2029 | 0.180 |
Why?
| | Curcumin | 1 | 2021 | 25 | 0.170 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 299 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 191 | 0.170 |
Why?
| | Middle Aged | 17 | 2025 | 35875 | 0.170 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 77 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 501 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 486 | 0.170 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 105 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 153 | 0.160 |
Why?
| | Niacinamide | 1 | 2021 | 86 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2022 | 248 | 0.160 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.160 |
Why?
| | Methionine | 1 | 2021 | 162 | 0.160 |
Why?
| | Organ Size | 2 | 2025 | 463 | 0.160 |
Why?
| | Benzamides | 3 | 2009 | 224 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 411 | 0.160 |
Why?
| | Nephrectomy | 1 | 2021 | 158 | 0.150 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 47 | 0.150 |
Why?
| | Cannabidiol | 1 | 2022 | 136 | 0.150 |
Why?
| | Pain | 1 | 2025 | 779 | 0.150 |
Why?
| | Vasodilation | 3 | 2018 | 523 | 0.150 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 96 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 27 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 86 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 304 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.140 |
Why?
| | Vitamin D | 2 | 2019 | 400 | 0.140 |
Why?
| | Blood Proteins | 1 | 2020 | 249 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 151 | 0.140 |
Why?
| | Brain | 2 | 2013 | 2933 | 0.140 |
Why?
| | Glucose | 2 | 2017 | 1047 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 68 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 191 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 430 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 266 | 0.130 |
Why?
| | Phenotype | 3 | 2022 | 3162 | 0.130 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 46 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 49 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 318 | 0.130 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 210 | 0.130 |
Why?
| | Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 63 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2013 | 790 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 596 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 57 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 315 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 128 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 88 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 80 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 138 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 192 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.130 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 55 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 175 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 2018 | 284 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2018 | 251 | 0.120 |
Why?
| | Brachial Artery | 4 | 2019 | 206 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 69 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 357 | 0.120 |
Why?
| | Breast | 1 | 2017 | 158 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1169 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 86 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 120 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 242 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 180 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.120 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.120 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Premature Birth | 1 | 2019 | 380 | 0.110 |
Why?
| | Enzyme Activation | 1 | 2017 | 766 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2115 | 0.110 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 31 | 0.110 |
Why?
| | Fishes | 1 | 2016 | 108 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 354 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 529 | 0.110 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 38 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 300 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 186 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 428 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 142 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 636 | 0.110 |
Why?
| | Serine | 1 | 2015 | 145 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 368 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 167 | 0.100 |
Why?
| | DNA Methylation | 1 | 2019 | 681 | 0.100 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 458 | 0.100 |
Why?
| | Child, Preschool | 3 | 2025 | 11787 | 0.100 |
Why?
| | Tidal Volume | 1 | 2014 | 111 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 1030 | 0.100 |
Why?
| | Cannabis | 1 | 2021 | 509 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 22 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 1000 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 300 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1306 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 339 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 111 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1966 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 104 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2018 | 708 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2112 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2363 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 621 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 383 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4109 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 59 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 55 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1886 | 0.090 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 75 | 0.090 |
Why?
| | Ion Transport | 1 | 2012 | 63 | 0.090 |
Why?
| | K562 Cells | 2 | 2009 | 93 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Gluconeogenesis | 1 | 2012 | 83 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 109 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 89 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 20 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1003 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2925 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5868 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 186 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 180 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 653 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 869 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Administration, Oral | 3 | 2026 | 847 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 237 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 195 | 0.080 |
Why?
| | Fatty Acids | 1 | 2014 | 450 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3333 | 0.080 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 204 | 0.080 |
Why?
| | Models, Animal | 1 | 2013 | 392 | 0.080 |
Why?
| | Aged | 7 | 2025 | 25913 | 0.080 |
Why?
| | Artifacts | 1 | 2011 | 139 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1098 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 293 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 823 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 59 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 27 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 130 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 380 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1173 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 179 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 102 | 0.080 |
Why?
| | Drug Approval | 1 | 2010 | 89 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 358 | 0.080 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.070 |
Why?
| | Heart Ventricles | 2 | 2024 | 760 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2013 | 4154 | 0.070 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.070 |
Why?
| | Risk Assessment | 1 | 2018 | 3671 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 119 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1782 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 128 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1985 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 549 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 318 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 601 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1732 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 222 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 213 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 302 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 164 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2430 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 20 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 527 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 548 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 384 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 676 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 173 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 128 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 49 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1263 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1125 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 533 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 420 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 266 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2201 | 0.060 |
Why?
| | Renal Circulation | 1 | 2025 | 75 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 449 | 0.060 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1767 | 0.050 |
Why?
| | Isomerism | 1 | 2024 | 57 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1769 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2008 | 395 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1953 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10779 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3154 | 0.050 |
Why?
| | Palliative Care | 2 | 2024 | 1002 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1256 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 137 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 251 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3077 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 323 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 54 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 55 | 0.050 |
Why?
| | Androstanols | 1 | 2022 | 30 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1047 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 80 | 0.040 |
Why?
| | Drug Interactions | 2 | 2017 | 398 | 0.040 |
Why?
| | Steroids | 1 | 2022 | 160 | 0.040 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 34 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2882 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 205 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 138 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 103 | 0.040 |
Why?
| | Pregnancy | 3 | 2019 | 7190 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 164 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 76 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 63 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 32 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 25 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 216 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5960 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 139 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 155 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 149 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 295 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1253 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 499 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 105 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1273 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 93 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 162 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 797 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 506 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 187 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 25 | 0.030 |
Why?
| | Rewarming | 1 | 2018 | 21 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 80 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2182 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 189 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 522 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 207 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1720 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 190 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 151 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1095 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 391 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 560 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 310 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 65 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1087 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 224 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 354 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 37 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2027 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 611 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 485 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 142 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 688 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 397 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 969 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 316 | 0.030 |
Why?
| | Safety | 1 | 2017 | 356 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 243 | 0.030 |
Why?
| | Larva | 1 | 2016 | 242 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 21 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 30 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 574 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 411 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 318 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 89 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 902 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1627 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1539 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 57 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4282 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 100 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 13 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1511 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 135 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1329 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 115 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 42 | 0.020 |
Why?
| | Orchiectomy | 1 | 2013 | 74 | 0.020 |
Why?
| | Altitude | 1 | 2017 | 473 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 320 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2015 | 514 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 41 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 53 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 173 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 706 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 191 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 76 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 341 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 21 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 153 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 197 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 173 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1813 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1121 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 238 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 205 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 143 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 609 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 588 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 80 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 88 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 707 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 242 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1455 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 289 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2273 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 198 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 2 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 635 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 55 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 23 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 526 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 675 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 863 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 404 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 407 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 55 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 175 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 112 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2438 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 396 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1382 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 370 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1821 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 8 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 824 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 86 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 203 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 131 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 170 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 17066 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 144 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2527 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 905 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1887 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 441 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 346 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 983 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2155 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2930 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2947 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4564 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1640 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 421 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2608 | 0.010 |
Why?
| | United States | 1 | 2010 | 15966 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|